.png "Cytosorbents Corp (NASDAQ: CTSO)")
B.Riley FBR analyst Andrew D’silva maintained a Buy rating on Cytosorbents Corp (CTSO) today and set a price target of $13.50. The company’s shares closed on Friday at $7.66, close to its 52-week low of $6.70.
D’silva noted:
“CytoSorbents Corporation (CTSO) reports 1Q19 results, and will hold a conference call at 4:45 p.m. ET (1:45 p.m. PT) the same day. (The dial-in and conference ID numbers are 877.451.6152 and 13690052, respectively.) We are comfortable with our estimates from our last earnings update note, and believe the thesis we outlined remains intact. We think consensus’ estimates, which call for a slightly higher top line and slightly lower bottom line, are reasonable, as well.”
According to TipRanks.com, D’silva is a 4-star analyst with an average return of 7.0% and a 38.7% success rate. D’silva covers the Healthcare sector, focusing on stocks such as EyePoint Pharmaceuticals Inc, Sensus Healthcare Inc, and Anixa Biosciences Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cytosorbents Corp with a $15.50 average price target.
See today’s analyst top recommended stocks >>
Based on Cytosorbents Corp’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $5.4 million. In comparison, last year the company had a GAAP net loss of $2.98 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CytoSorbents Corp. engages in the research and development of blood purification technology for the reduction of deadly uncontrolled inflammation in hospitalized patients. Its product include CytoSorb, ContrastSorb, HemoDefend, VetResQ, and DrugSorb. The company was founded by Joseph Rubin on April 25, 2002 and is headquartered in Monmouth Junction, NJ.
